<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
----------------------
Date of Report (Date of earliest event reported): MAY 7, 1996
-----------
CREATIVE BIOMOLECULES, INC.
--------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 0-19910 94-2786743
-------- ------- ----------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
45 SOUTH STREET, HOPKINTON, MASSACHUSETTS 01748
-----------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (508) 435-9001
--------------
1
<PAGE> 2
ITEM 5. OTHER EVENTS.
- ------ ------------
On May 7, 1996, the Registrant publicly disseminated a press release
announcing that researchers at the Registrant and academic collaborators
presented data on the role of OP-1 in kidney development and in restoring
renal function in animal models of acute renal failure. OP-1 is a member of a
large superfamily of proteins that are involved in embryonic development and
tissue formation. The data was presented at the Acute Renal Failure in the 21st
Century Conference sponsored by the National Institutes of Health.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
- ------ ---------------------------------
(c) Exhibits.
99.1 The Registrant's Press Release dated May 7, 1996.
2
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Creative BioMolecules, Inc.
--------------------------------
(Registrant)
Date: May 7, 1996 /s/ Wayne E. Mayhew III
-----------------------
Wayne E. Mayhew III
Vice President, Chief Financial
Officer, Treasurer and Secretary
<PAGE> 1
CONTACTS: STEPHANIE K. MARRUS
V.P., CORPORATE DEVELOPMENT
CREATIVE BIOMOLECULES, INC.
(508) 435-9001
ROBERT GOTTLIEB
FEINSTEIN PARTNERS INC.
(617) 577-8110
FOR IMMEDIATE RELEASE
- ---------------------
RESEARCHERS PRESENT FIRST PRECLINICAL STUDIES SUGGESTING OP-1 CAN
PROTECT AGAINST ACUTE RENAL FAILURE
DATA PRESENTED AT THE ACUTE RENAL FAILURE IN THE 21ST CENTURY CONFERENCE
AT THE NIH
Hopkinton, Mass., May 7, 1996. Researchers at Creative BioMolecules, Inc. and
academic collaborators presented data on the role of OP-1 in kidney development
and in restoring renal function in animal models of acute renal failure. OP-1 is
a member of a large superfamily of proteins that are involved in embryonic
development and tissue formation. The data was presented yesterday at the Acute
Renal Failure in the 21st Century Conference sponsored by the National
Institutes of Health.
The rationale for the use of OP-1 in treating kidney disease is based on data
that demonstrate the protein is involved in the formation of the kidney during
embryonic development. These data support previous findings that showed OP-1
deficient mice in knockout studies failed to develop mature kidneys. Additional
data was presented to show that levels of OP-1 in the kidney correlate with
disease progression. Investigators also presented two independent studies that
showed that OP-1 could restore renal function in an animal model of acute renal
injury.
"Collectively, these results and data from other studies suggest that OP-1 may
provide a basis for the treatment of both acute and chronic renal disease.
Follow-on studies are in progress to extend these very encouraging preliminary
observations," said Charles Cohen, Ph.D., Chief Scientific Officer of Creative
BioMolecules.
Acute renal failure is the rapid and sudden loss of the kidneys' ability to
perform their essential functions. The primary causes of acute renal failure are
interruptions of blood flow, trauma and certain medications with toxic side
effects to the kidneys. Currently, there are no therapies that improve recovery
or reduce the extent of kidney injury from acute renal failure, which is often
associated with multiple organ failure and a high mortality rate.
Creative BioMolecules is a discovery and development company focused on
proprietary protein-based therapeutics for human tissue regeneration and
restoration. The Company's therapeutics are based on proteins that act as
signals in initiating and regulating the cellular events involved in cell and
tissue formation.
# # #
